

Mansi Purwar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11176658/publications.pdf>

Version: 2024-02-01

13
papers

989
citations

1040056

9
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

2143
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1923-1932.	4.0	33
2	Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. <i>Nature Communications</i> , 2022, 13, 695.	12.8	2
3	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	3.8	5
4	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. <i>EClinicalMedicine</i> , 2021, 31, 100689.	7.1	206
5	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. <i>IScience</i> , 2021, 24, 102699.	4.1	15
6	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	4.9	3
7	Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. <i>Cell Reports Medicine</i> , 2021, 2, 100420.	6.5	28
8	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	6.0	36
9	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	57
10	Immunogenicity of a DNA vaccine candidate for COVID-19. <i>Nature Communications</i> , 2020, 11, 2601.	12.8	514
11	Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. <i>Vaccine</i> , 2018, 36, 6345-6353.	3.8	6
12	Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. <i>Journal of Biological Chemistry</i> , 2018, 293, 15002-15020.	3.4	11
13	Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2013, 288, 9815-9825.	3.4	28